Literature DB >> 29286395

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing.

Jingfeng Wang1, Zhenning Nie1, Haiyan Chen2, Xianhong Shu2, Zhaohua Yang3, Ruiming Yao1, Yangang Su4, Junbo Ge1.   

Abstract

It is now well recognized that heart failure (HF) patients with left bundle branch block (LBBB) derive substantial clinical benefits from cardiac resynchronization therapy (CRT), and LBBB has become one of the important predictors for CRT response. The conventional tachypacing-induced HF model has several major limitations, including absence of stable LBBB and rapid reversal of left ventricular (LV) dysfunction after cessation of pacing. Hence, it is essential to establish an optimal model of chronic HF with isolated LBBB for studying CRT benefits. In the present study, a canine model of asynchronous HF induced by left bundle branch (LBB) ablation and 4 weeks of rapid right ventricular (RV) pacing is established. The RV and right atrial (RA) pacing electrodes via the jugular vein approach, together with an epicardial LV pacing electrode, were implanted for CRT performance. Presented here are the detailed protocols of radiofrequency (RF) catheter ablation, pacing leads implantation, and rapid pacing strategy. Intracardiac and surface electrograms during operation were also provided for a better understanding of LBB ablation. Two-dimensional speckle tracking imaging and aortic velocity time integral (aVTI) were acquired to validate the chronic stable HF model with LV asynchrony and CRT benefits. By coordinating ventricular activation and contraction, CRT uniformed the LV mechanical work and restored LV pump function, which was followed by reversal of LV dilation. Moreover, the histopathological study revealed a significant restoration of cardiomyocyte diameter and collagen volume fraction (CVF) after CRT performance, indicating a histologic and cellular reverse remodeling elicited by CRT. In this report, we described a feasible and valid method to develop a chronic asynchronous HF model, which was suitable for studying structural and biologic reverse remodeling following CRT.

Entities:  

Mesh:

Year:  2017        PMID: 29286395      PMCID: PMC5755552          DOI: 10.3791/56439

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  22 in total

Review 1.  Echocardiographic optimization of the atrioventricular and interventricular intervals during cardiac resynchronization.

Authors:  S Serge Barold; Arzu Ilercil; Bengt Herweg
Journal:  Europace       Date:  2008-11       Impact factor: 5.214

Review 2.  Animal models of heart failure: a scientific statement from the American Heart Association.

Authors:  Steven R Houser; Kenneth B Margulies; Anne M Murphy; Francis G Spinale; Gary S Francis; Sumanth D Prabhu; Howard A Rockman; David A Kass; Jeffery D Molkentin; Mark A Sussman; Walter J Koch; Walter Koch
Journal:  Circ Res       Date:  2012-05-17       Impact factor: 17.367

Review 3.  Predictors of response to cardiac resynchronization therapy: A systematic review.

Authors:  John Rickard; Henry Michtalik; Ritu Sharma; Zackary Berger; Emmanuel Iyoha; Ariel R Green; Nowreen Haq; Karen A Robinson
Journal:  Int J Cardiol       Date:  2016-09-25       Impact factor: 4.164

4.  Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults.

Authors:  Niels Risum; Sophia Ali; Niels T Olsen; Christian Jons; Michel G Khouri; Trine K Lauridsen; Zainab Samad; Eric J Velazquez; Peter Sogaard; Joseph Kisslo
Journal:  J Am Soc Echocardiogr       Date:  2012-09-12       Impact factor: 5.251

5.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

6.  Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure.

Authors:  Pietro Francia; Cristina Balla; Agnese Ricotta; Arianna Uccellini; Alessandra Frattari; Anna Modestino; Marina Borro; Maurizio Simmaco; Adriano Salvati; Luciano De Biase; Massimo Volpe
Journal:  Int J Cardiol       Date:  2010-09-21       Impact factor: 4.164

7.  Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure.

Authors:  Jingfeng Wang; Xue Gong; Haiyan Chen; Shengmei Qin; Nianwei Zhou; Yangang Su; Junbo Ge
Journal:  J Cardiovasc Electrophysiol       Date:  2017-03-06

8.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy.

Authors:  Pavel Osmancik; Dalibor Herman; Petr Stros; Hana Linkova; Karel Vondrak; Eva Paskova
Journal:  Cardiology       Date:  2013-03-12       Impact factor: 1.869

10.  Cardiac resynchronization therapy cures dyssynchronopathy in canine left bundle-branch block hearts.

Authors:  Kevin Vernooy; Richard N M Cornelussen; Xander A A M Verbeek; Ward Y R Vanagt; Arne van Hunnik; Marion Kuiper; Theo Arts; Harry J G M Crijns; Frits W Prinzen
Journal:  Eur Heart J       Date:  2007-07-04       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.